Langerhans cell histiocytosis and hypercalcemia: clinical response to indomethacin
1Division of Pediatric Hematology-Oncology, Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115-6084, USA.
Purpose:
Hypercalcemia is a known complication of childhood malignancies but has never been reported to be associated with Langerhans cell histiocytosis (LCH) in a pediatric patient.
Patients And Methods:
We describe an infant with multisystem LCH who developed hypercalcemia on two occasions. After being placed on indomethacin, the hypercalcemia did not recur despite disease progression.
Conclusion:
Hypercalcemia may complicate LCH. If it is demonstrated, indomethacin should be considered as a treatment.
More Related Videos
10:01Analysis of T-cell Receptor-Induced Calcium Influx in Primary Murine T-cells by Full Spectrum Flow Cytometry
Published on: December 16, 2022
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014